Delcath Systems (NASDAQ:DCTH) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $22.00 price objective on the stock.

DCTH has been the topic of a number of other research reports. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Delcath Systems currently has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $12.69 on Tuesday. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $13.30. The company has a 50 day moving average price of $11.33 and a 200 day moving average price of $9.83. The stock has a market capitalization of $405.75 million, a P/E ratio of -9.40 and a beta of 0.87.

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently bought and sold shares of the business. Marshall Wace LLP lifted its holdings in Delcath Systems by 7.0% during the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after buying an additional 6,066 shares during the last quarter. Geode Capital Management LLC lifted its stake in Delcath Systems by 3.0% during the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after purchasing an additional 7,298 shares during the last quarter. State Street Corp boosted its holdings in Delcath Systems by 12.4% in the third quarter. State Street Corp now owns 85,457 shares of the company’s stock valued at $772,000 after purchasing an additional 9,400 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Delcath Systems in the third quarter valued at approximately $102,000. Finally, Barclays PLC purchased a new position in Delcath Systems in the third quarter valued at approximately $104,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.